Oculis Holding AG (FRA:CR5) Beta: 0.7721 (As of Jun. 30, 2026)


FRA:CR5 Oculis Holding AG FRA:CR5
28 GF Score
Price €9.76
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG Beta?

Oculis Holding AG FRA:CR5 +1.67% 28 Beta is 0.7721 as of Jun. 30, 2026. GuruFocus rates FRA:CR5 with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-30), Oculis Holding AG's Beta is 0.7721.


Oculis Holding AG  (FRA:CR5) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Oculis Holding AG Beta Related Terms


Oculis Holding AG Beta Historical Data

* Premium members only.

The historical data trend for Oculis Holding AG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oculis Holding AG Beta Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oculis Holding AG Quarterly Data
Dec20 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:CR5 vs NVCT, AURA, CADL: Beta Comparison

For the Biotechnology subindustry, Oculis Holding AG's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oculis Holding AG Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Beta distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Beta falls into.


FRA:CR5
28GF Score
Oculis Holding AG FRA:CR5
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oculis Holding AG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.7721 mean?
Oculis Holding AG (FRA:CR5) has a Beta of 0.7721 as of Jun. 30, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Oculis Holding AG and its competitors.
Is Oculis Holding AG's Beta too high?
Oculis Holding AG's current Beta is 0.7721. Overall, Oculis Holding AG has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's Beta compare to NVCT and AURA?
Oculis Holding AG's Beta of 0.7721 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Oculis Holding AG and its competitors. Oculis Holding AG's current Beta is 0.7721. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (FRA:CR5) has a current Beta of 0.7721. The current Beta is 0.7721. Oculis Holding AG's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Oculis Holding AG (FRA:CR5), the current Beta is 0.7721 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oculis Holding AG Business Description

Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
28GF Score

Get the complete analysis for FRA:CR5

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.76
Price